Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Articles|November 16, 2021
Daily OTC Pearl: Flonase (Fluticasone) Nasal Spray
Author(s)Saro Arakelians, PharmD
Nonprescription fluticasone nasal spray is used to relieve symptoms of rhinitis, such as sneezing and itchy, watery eyes.
Advertisement
OTC/Lifestyle Pearl of the Day: Flonase (Fluticasone) Nasal Spray
Indication: Nonprescription fluticasone nasal spray (Flonase Allergy) is used to relieve symptoms of rhinitis, such as sneezing and a runny, stuffy, or itchy nose; and itchy, watery eyes caused by hay fever or other allergies (caused by an allergy to pollen, mold, dust, or pets).
Insight
- Flonase comes in Sensimist, regular dosage, and children’s dosage.
- Flonase nasal sprays act on multiple inflammatory substances (histamine, prostaglandins, cytokines, tryptases, chemokines, and leukotrienes).
- Flonase products relieve a wide range of symptoms, providing 24-hour relief from nasal congestion, itchy eyes, watery eyes, runny nose, itchy nose, and sneezing.
- Flonase is indicated for itchy, watery eyes in adults and children 12 years of age and older.
- The main difference with Flonase Sensimist is that its patented MistPro Technology delivers a fine mist. The alcohol-free spray is virtually no-drip and features the shortest nozzle of any allergy spray.
- Dosing: The recommended starting dosage in adults is 2 sprays (50 mcg of fluticasone propionate each) in each nostril once daily (total daily dose, 200 mcg).
- Manufacturer: GSK
Sources:
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5